Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 ...
Initial INHBE data in 2H25 Will be the Next Catalyst. WVE expects to report safety and tolerability, as well as biomarker data that could reflect healthy weight loss from the placebo-controlled study (NCT06842186). We would expect positive stock reaction if the data show dose-dependent knockdown of
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company’s second quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wa...
A director at Western Asset High Income Opportunity Fund Inc maiden bought 10,000 shares at 4.018USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with st...
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET. A live webcast of this presentation can be acce...
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical development of Wave’s robust RNA medicines pipeline CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave’s e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.